{"id":391566,"date":"2014-09-02T00:00:00","date_gmt":"2014-09-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0514-biopharma-psoriatic-arthritis-pharmacor-g7-2014\/"},"modified":"2026-03-31T09:04:47","modified_gmt":"2026-03-31T09:04:47","slug":"pcorim0514-biopharma-psoriatic-arthritis-pharmacor-g7-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0514-biopharma-psoriatic-arthritis-pharmacor-g7-2014\/","title":{"rendered":"Psoriatic Arthritis | Pharmacor | G7 | 2014"},"content":{"rendered":"<p>Psoriatic arthritis (PsA) is a disease hallmarked by psoriatic skin lesions and erosive joint damage that remains poorly understood, underdiagnosed, and undertreated. Nevertheless, tumor necrosis-alpha (TNF-\u03b1) inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. Several novel therapies with alternative mechanisms of action are expected to launch for PsA during the 2013-2023 study period, and thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies.<\/p>\n<p>The recent launches of the interleukin-12\/-23 (IL-12\/23) inhibitor ustekinumab (Janssen\u2019s Stelara) and the oral phosphodiesterase-4 (PDE-4) inhibitor apremilast (Celgene\u2019s Otezla) have heralded the post-TNF-\u03b1 inhibitor era in the PsA market. In this report, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF-\u03b1 inhibitor class.<\/p>\n","protected":false},"template":"","class_list":["post-391566","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391566\/revisions"}],"predecessor-version":[{"id":394689,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391566\/revisions\/394689"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}